Amanote Research
Register
Sign In
331. Phase I Study of the “Triad” Autologous (FANG™) Vaccine, Incorporating Bifunctional shRNAfurin and GMCSF Transgene Expression, in Advanced Cancer Patients
Molecular Therapy
- United States
doi 10.1016/s1525-0016(16)36135-4
Full Text
Open PDF
Abstract
Available in
full text
Categories
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Date
May 1, 2012
Authors
Unknown
Publisher
Elsevier BV
Related search
203. Phase I Study of the “Triad” Autologous (FANG™) Vaccine, Incorporating Bifunctional shRNAfurin and GMCSF Transgene Expression, in Advanced Ewing's Sarcoma: Preliminary Data in Pediatrics Patients
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Phase I Study of Temozolomide in Paediatric Patients With Advanced Cancer
British Journal of Cancer
Cancer Research
Oncology
206. FANG™ Cytokine Expression Analyses Update
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
666. Phase I Study Results of Pbi-shRNA™ STMN1 Nanoplex via Intratumoral Injection in Advanced Cancer
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients With Advanced Cancer
Clinical Cancer Research
Cancer Research
Oncology
Docetaxel and Cisplatin in Patients With Advanced Gastric Cancer: Results of Japanese Phase I/Ii Study
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of CXD101 in Patients With Advanced Cancer
Cancer
Cancer Research
Oncology
Phase I Study of TAS-102 and Irinotecan Combination Therapy in Japanese Patients With Advanced Colorectal Cancer
Investigational New Drugs
Oncology
Pharmacology
A Phase I Study of Indoximod in Patients With Advanced Malignancies
Oncotarget
Oncology
